Lebrikizumab 250mg/2ml solution for injection pre-filled disposable devices
NHS hospitals in England used £16,716,474 of indicative cost of Lebrikizumab 250mg/2ml solution for injection pre-filled disposable devices in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 314.1% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Lebrikizumab 250mg/2ml solution for injection pre-filled disposable devices: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Lebrikizumab 250mg/2ml solution for injection pre-filled disposable devices most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Guy's & St Thomas' Nhs Foundation Trust | £1,268,499 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,028,881 |
| Dudley Group Nhs Foundation Trust | £779,042 |
| Leeds Teaching Hpls Nhs Trust | £708,633 |
| Barts Health Nhs Trust | £633,682 |
| Aintree University Hospital Nhs Ft | £615,511 |
| Univ Hpls Bristol Nhs Foundation Trust | £608,698 |
| University Hospitals Of Morecambe Bay | £578,036 |
| West Hertfordshire Hospitals Nhs Trust | £488,321 |
| East Lancashire Hospitals Nhs Trust | £454,252 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.